Fisher, D. J., Vale, C. L., Rydzewska, L. H., Godolphin, P., Agarwal, N., Attard, G., Chi, K. N., Clarke, N. W., Davis, I. D., Fizazi, K., Gillessen, S., James, N. D., Matheson, D. J., Oldroyd, R., Parmar, M. K. B., Sweeney, C., Tombal, B. F., White, I. R., Tierney, J. F. (2025). Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.20